Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.
Wojciech JurczakNagah ElmusharafChristopher Paul FoxWilliam M TownsendAmanda G PaulovichJeffrey R WhiteakerFanny KrantzChuan-Chuan WunGraeme ParrShringi SharmaVeerendra MunugalavadlaRicha ManwaniEmma DeanTahla MunirPublished in: Therapeutic advances in hematology (2023)
NCT03328273.